FFRCT对医疗实践与临床结局的1年影响:ADVANCE注册研究
ADVANCE国际注册研究前瞻性纳入5083例因临床疑似冠心病行冠状动脉CTA并检出动脉粥样硬化的患者,评估FFRCT与后续治疗及1年临床结局的关系。FFRCT≤0.80组血运重建率38.40%显著高于FFRCT>0.80组的5.60%(RR 6.87),FFRCT>0.80组心血管死亡或MI显著更低(RR 4.22),MACE及全因死亡或MI差异未达统计学显著。
要点
- FFRCT≤0.80者1年血运重建率38.40%,显著高于FFRCT>0.80者的5.60%(RR 6.87)。
- FFRCT>0.80者心血管死亡或MI发生率0.20%,显著低于FFRCT≤0.80者的0.80%(RR 4.22)。
- FFRCT>0.80者MACE及全因死亡或MI均较低,但差异未达统计学显著(RR 1.81与1.92,P=0.06)。
核心结论
- ADVANCE FFRCT注册研究1年结局显示所有患者事件率均低,FFRCT阴性者血运重建更少、MACE有降低趋势且心血管死亡或MI显著低于FFRCT异常者。
研究设计与样本
- 国际前瞻性注册研究,38个国际中心,2015年7月15日至2017年10月20日纳入5083例临床疑似冠心病且冠状动脉CTA检出动脉粥样硬化的患者。
诊断标准与关键数值
- FFRCT≤0.80组血运重建1208例(38.40%),FFRCT>0.80组89例(5.60%),RR 6.87(95%CI 5.59–8.45),P<0.001。
- FFRCT≤0.80组MACE 43例,FFRCT>0.80组12例,RR 1.81(95%CI 0.96–3.43),P=0.06,未达统计学显著。
- FFRCT≤0.80组全因死亡或MI 38例(1.20%),FFRCT>0.80组10例(0.60%),RR 1.92(95%CI 0.96–3.85),P=0.06,未达统计学显著。
- FFRCT≤0.80组心血管死亡或MI 25例(0.80%),FFRCT>0.80组3例(0.20%),RR 4.22(95%CI 1.28–13.95),P=0.01。
局限性
- 1年随访时449例患者无随访数据。
- MACE及全因死亡或MI的组间差异未达统计学显著(RR 1.81,95%CI 0.96–3.43,P=0.06;RR 1.92,95%CI 0.96–3.85,P=0.06)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The 1-year data from the international ADVANCE (Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care) Registry of patients undergoing coronary computed tomography angiography (CTA) was used to evaluate the relationship of fractional flow reserve derived from coronary CTA (FFRCT) with downstream care and clinical outcomes.
BACKGROUND: Guidelines for management of chest pain using noninvasive imaging pathways are based on short- to intermediate-term outcomes.
METHODS: Patients (N = 5,083) evaluated for clinically suspected coronary artery disease and in whom atherosclerosis was identified by coronary CTA were prospectively enrolled at 38 international sites from July 15, 2015, to October 20, 2017. Demographics, symptom status, coronary CTA and FFRCT findings and resultant site-based treatment plans, and clinical outcomes through 1 year were recorded and adjudicated by a blinded core laboratory. Major adverse cardiac events (MACE), death, myocardial infarction (MI), and acute coronary syndrome leading to urgent revascularization were captured.
RESULTS: At 1 year, 449 patients did not have follow-up data. Revascularization occurred in 1,208 (38.40%) patients with an FFRCT ≤0.80 and in 89 (5.60%) with an FFRCT >0.80 (relative risk [RR]: 6.87; 95% confidence interval [CI]: 5.59 to 8.45; p < 0.001). MACE occurred in 55 patients, 43 events occurred in patients with an FFRCT ≤0.80 and 12 occurred in those with an FFRCT >0.80 (RR: 1.81; 95% CI: 0.96 to 3.43; p = 0.06). Time to first event (all-cause death or MI) occurred in 38 (1.20%) patients with an FFRCT ≤0.80 compared with 10 (0.60%) patients with an FFRCT >0.80 (RR: 1.92; 95% CI: 0.96 to 3.85; p = 0.06). Time to first event (cardiovascular death or MI) occurred cardiovascular death or MI occurred more in patients with an FFRCT ≤0.80 compared with patients with an FFRCT >0.80 (25 [0.80%] vs. 3 [0.20%]; RR: 4.22; 95% CI: 1.28 to 13.95; p = 0.01).
CONCLUSIONS: The 1-year outcomes from the ADVANCE FFRCT Registry show low rates of events in all patients, with less revascularization and a trend toward lower MACE and significantly lower cardiovascular death or MI in patients with a negative FFRCT compared with patients with abnormal FFRCT values. (Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Wave [ADVANCE]; NCT02499679).
引用
- Patel MR, Nørgaard BL, Fairbairn TA, et al. 1-Year Impact on Medical Practice and Clinical Outcomes of FFRCT: The ADVANCE Registry. JACC Cardiovasc Imaging. 2019. PMID: 31005540. doi:10.1016/j.jcmg.2019.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。